Drug interactions
Daunorubicin + Osimertinib
Severity: Minor
Daunorubicin and Osimertinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Osimertinib inhibits the BCRP efflux transporter, which may raise systemic exposure to BCRP substrates. Daunorubicin exposure could rise modestly, with a possible increase in myelosuppression or cardiotoxicity.
What this interaction means in plain words
Daunorubicin and Osimertinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Daunorubicin belongs to Oncology; Osimertinib belongs to Oncology.
Why it happens
Osimertinib inhibits BCRP-mediated efflux, potentially reducing daunorubicin elimination.
What to do
Monitor blood counts and cardiac function during combined use. Reduce the daunorubicin dose if excess toxicity appears.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Daunorubicin and Osimertinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Daunorubicin
- Adenovirus types 4 and 7 live + Daunorubicin Contraindicated
- Belatacept + Daunorubicin Major
- Cyclosporine + Daunorubicin Major
- Cyclosporin + Daunorubicin Major
- Daunorubicin + Dengue vaccine Major
- Daunorubicin + Etrasimod Major
Other interactions of Osimertinib
Frequently asked questions
Can I take Daunorubicin with Osimertinib?
MediHelp rates the interaction as minor. Daunorubicin and Osimertinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Osimertinib inhibits the BCRP efflux transporter, which may raise systemic exposure to BCRP substrates. Daunorubicin exposure could rise modestly, with a possible increase in myelosuppression or cardiotoxicity.
How serious is the interaction between Daunorubicin and Osimertinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function during combined use. Reduce the daunorubicin dose if excess toxicity appears.
What other medicines interact with Daunorubicin?
MediHelp also lists interactions of Daunorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cyclosporine. The full list is on the Daunorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
